Title:
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF NEUROGENIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2012/133489
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical product which has a sufficient curative effect on multiple sclerosis and has excellent autoimmune inhibitory activity, while being reduced in the side effects which steroidal agents and interferon β have. The present invention relates to a pharmaceutical composition for the treatment or prophylaxis of multiple sclerosis, which contains, as an active ingredient, 4-(2-aminopyridin-4-yl)-3- (4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1H-pyrazole or a pharmacologically acceptable salt thereof.
More Like This:
Inventors:
HAGIHARA MASAHIKO
MATSUNAGA HIROFUMI
KASUYA YOSHITOSHI
NAMIKI KANA
MATSUNAGA HIROFUMI
KASUYA YOSHITOSHI
NAMIKI KANA
Application Number:
PCT/JP2012/058067
Publication Date:
October 04, 2012
Filing Date:
March 28, 2012
Export Citation:
Assignee:
UBE INDUSTRIES (JP)
UNIV CHIBA NAT UNIV CORP (JP)
HAGIHARA MASAHIKO
MATSUNAGA HIROFUMI
KASUYA YOSHITOSHI
NAMIKI KANA
UNIV CHIBA NAT UNIV CORP (JP)
HAGIHARA MASAHIKO
MATSUNAGA HIROFUMI
KASUYA YOSHITOSHI
NAMIKI KANA
International Classes:
A61K31/501; A61P25/00; C07D401/14
Domestic Patent References:
| WO2004029043A1 | 2004-04-08 |
Other References:
NAMIKI, K. ET AL.: "Role of p38 in experimental autoimmune encephalomyelitis", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 109, no. 1, 2009, pages 102P
LU, L. ET AL.: "Role of SMAD and Non-SMAD Signals in the Development of Th17 and Regulatory T Cells", JOURNAL OF IMMUNOLOGY, vol. 184, 2010, pages 4295 - 4306
LU, L. ET AL.: "Role of SMAD and Non-SMAD Signals in the Development of Th17 and Regulatory T Cells", JOURNAL OF IMMUNOLOGY, vol. 184, 2010, pages 4295 - 4306
Attorney, Agent or Firm:
TSUKUNI & ASSOCIATES et al. (3-7-1 Kasumigaseki, Chiyoda-k, Tokyo 13, JP)
Download PDF:
Claims: